Goldman Sachs
MIRM icon

Goldman Sachs’s Mirum Pharmaceuticals MIRM Stock Holding History

Goldman Sachs’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.4M Sell
549,874
-112,432
-17% -$11.3M 0.01% 1594
2026
Q1 		$61.2M Sell
662,306
-62,011
-9% -$5.83M 0.01% 1417
2025
Q4 		$57.2M Buy
724,317
+273,479
+61% +$19.6M 0.01% 1404
2025
Q3 		$33.1M Buy
450,838
+55,830
+14% +$3.55M ﹤0.01% 1781
2025
Q2 		$20.1M Sell
395,008
-82,643
-17% -$3.68M ﹤0.01% 2125
2025
Q1 		$21.5M Sell
477,651
-77,985
-14% -$3.68M ﹤0.01% 1967
2024
Q4 		$23M Sell
555,636
-82,331
-13% -$3.43M ﹤0.01% 1997
2024
Q3 		$24.9M Sell
637,967
-121,051
-16% -$4.83M ﹤0.01% 1859
2024
Q2 		$26M Buy
759,018
+58,902
+8% +$1.54M ﹤0.01% 1674
2024
Q1 		$17.6M Buy
700,116
+243,798
+53% +$6.7M ﹤0.01% 1957
2023
Q4 		$13.5M Buy
456,318
+215,542
+90% +$6.52M ﹤0.01% 2256
2023
Q3 		$7.61M Sell
240,776
-34,120
-12% -$934K ﹤0.01% 2628
2023
Q2 		$7.11M Sell
274,896
-117,476
-30% -$3.12M ﹤0.01% 2782
2023
Q1 		$9.42M Sell
392,372
-49,403
-11% -$1.13M ﹤0.01% 2479
2022
Q4 		$8.61M Buy
441,775
+205,747
+87% +$4.07M ﹤0.01% 2708
2022
Q3 		$4.96M Buy
236,028
+114,220
+94% +$2.75M ﹤0.01% 3143
2022
Q2 		$2.37M Buy
121,808
+93,071
+324% +$2.2M ﹤0.01% 3902
2022
Q1 		$633K Sell
28,737
-12,536
-30% -$256K ﹤0.01% 5172
2021
Q4 		$658K Buy
+41,273
New +$642K ﹤0.01% 5184
2020
Q4 		– Sell
-22,919
Closed -$442K – 5617
2020
Q3 		$442K Sell
22,919
-8,021
-26% -$172K ﹤0.01% 4548
2020
Q2 		$602K Sell
30,940
-7,177
-19% -$120K ﹤0.01% 4271
2020
Q1 		$534K Buy
+38,117
New +$626K ﹤0.01% 4175
2019
Q4 		– Sell
-11,066
Closed -$111K – 5338
2019
Q3 		$111K Buy
+11,066
New +$136K ﹤0.01% 4950

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's MIRM Position: Q2 2026 in Review

Goldman Sachs reduced its Mirum Pharmaceuticals (MIRM) stake by 17% in Q2 2026, selling an estimated $11.3M and leaving 549,874 shares worth $64.4M. The position accounts for 0.01% of the portfolio, ranked #1594.

Goldman Sachs first reported a position in MIRM in Q3 2019 and has held it in 23 quarters since. 328 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Goldman Sachs held 549,874 shares of Mirum Pharmaceuticals worth $64.4M as of Q2 2026.
  • Goldman Sachs sold 112,432 Mirum Pharmaceuticals shares in Q2 2026, an estimated $11.3M.
  • Mirum Pharmaceuticals made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1594 holding.
  • Goldman Sachs first reported a position in Mirum Pharmaceuticals in Q3 2019 and has held it in 23 quarters since.
  • 328 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.